Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
Agreement gives patients a path to FDA-approved treatments at self-pay price through the Hims & Hers platform INDIANAPOLIS, Nov. 6, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Hims & Hers Health, Inc. (NYSE: HIMS) today announced an agreement to help expand access to...
Covered in this story
Analyst targets on Hims Hers Health Inc Class a
- Truist Securities: $28.5 → $32 by Oct 2027 · Hold via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $HIMS yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Hims Hers Health Inc Class a →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.